William Blair & Company’s Galectin Therapeutics GALT Stock Holding History

William Blair & Company’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$693K	Hold	149,283	–	–	﹤0.01%	1112
2026 Q1	$417K	Buy	149,283 +111,399	+294%	+$339K	﹤0.01%	1211
2025 Q4	$158K	Hold	37,884	–	–	﹤0.01%	1507
2025 Q3	$160K	Hold	37,884	–	–	﹤0.01%	1499
2025 Q2	$79.9K	Hold	37,884	–	–	﹤0.01%	1551
2025 Q1	$46.2K	Hold	37,884	–	–	﹤0.01%	1600
2024 Q4	$48.9K	Hold	37,884	–	–	﹤0.01%	1611
2024 Q3	$104K	Hold	37,884	–	–	﹤0.01%	1533
2024 Q2	$85.6K	Hold	37,884	–	–	﹤0.01%	1532
2024 Q1	$90.5K	Hold	37,884	–	–	﹤0.01%	1521
2023 Q4	$62.9K	Hold	37,884	–	–	﹤0.01%	1565
2023 Q3	$72.7K	Hold	37,884	–	–	﹤0.01%	1546
2023 Q2	$54.6K	Hold	37,884	–	–	﹤0.01%	1588
2023 Q1	$79.6K	Hold	37,884	–	–	﹤0.01%	1526
2022 Q4	$42.8K	Sell	37,884 -3,000	-7%	-$4K	﹤0.01%	1594
2022 Q3	$67K	Hold	40,884	–	–	﹤0.01%	1555
2022 Q2	$54K	Buy	+40,884	New	+$58.8K	﹤0.01%	1620
2021 Q4	–	Sell	-10,756	Closed	-$42K	–	1992
2021 Q3	$42K	Hold	10,756	–	–	﹤0.01%	1698
2021 Q2	$34K	Hold	10,756	–	–	﹤0.01%	1730
2021 Q1	$23K	Hold	10,756	–	–	﹤0.01%	1737
2020 Q4	$24K	Hold	10,756	–	–	﹤0.01%	1689
2020 Q3	$29K	Hold	10,756	–	–	﹤0.01%	1551
2020 Q2	$33K	Hold	10,756	–	–	﹤0.01%	1486
2020 Q1	$21K	Sell	10,756 -23,364	-68%	-$56.8K	﹤0.01%	1482
2019 Q4	$98K	Hold	34,120	–	–	﹤0.01%	1413
2019 Q3	$125K	Buy	34,120 +23,364	+217%	+$84.4K	﹤0.01%	1352
2019 Q2	$45K	Buy	+10,756	New	+$46.6K	﹤0.01%	1509

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

William Blair & Company's GALT Position: Q2 2026 in Review

William Blair & Company held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 149,283 shares worth $693K. The position accounts for ﹤0.01% of the portfolio, ranked #1112.

William Blair & Company first reported a position in GALT in Q2 2019 and has held it in 27 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

William Blair & Company held 149,283 shares of Galectin Therapeutics worth $693K as of Q2 2026.
William Blair & Company left its Galectin Therapeutics share count unchanged in Q2 2026.
Galectin Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1112 holding.
William Blair & Company first reported a position in Galectin Therapeutics in Q2 2019 and has held it in 27 quarters since.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.